Scotia Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Scotia Capital’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.78M	Buy	1,343,726 +1,548	+0.1%	+$10.7K	0.03%	242
2026 Q1	$7.24M	Buy	1,342,178 +55,995	+4%	+$451K	0.03%	246
2025 Q4	$9.6M	Buy	1,286,183 +8,298	+0.6%	+$51.1K	0.04%	213
2025 Q3	$7.25M	Sell	1,277,885 -14,104	-1%	-$76.7K	0.03%	244
2025 Q2	$6.98M	Sell	1,291,989 -260,690	-17%	-$1M	0.03%	235
2025 Q1	$5.07M	Buy	1,552,679 +160,960	+12%	+$556K	0.03%	264
2024 Q4	$4.26M	Sell	1,391,719 -4,562	-0.3%	-$13.5K	0.02%	293
2024 Q3	$3.49M	Buy	1,396,281 +29,230	+2%	+$76.9K	0.02%	328
2024 Q2	$3.5M	Buy	+1,367,051	New	+$3.8M	0.02%	308

Other funds holding EPRX

BGC

Beutel, Goodman & Co Toronto, Ontario, Canada $13.6B AUM 17.82% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Jupiter Topco New York $245B AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Scotia Capital's EPRX Position: Q2 2026 in Review

Scotia Capital increased its Eupraxia Pharmaceuticals (EPRX) stake by 0.12% in Q2 2026, buying an estimated $10.7K and bringing the position to 1,343,726 shares worth $8.78M. The position accounts for 0.03% of the portfolio, ranked #242.

Scotia Capital first reported a position in EPRX in Q2 2024 and has held it in 9 quarters since. The position peaked at $9.6M in Q4 2025. 67 funds tracked by Wall St. Rank hold EPRX as of Q2 2026.

Scotia Capital held 1,343,726 shares of Eupraxia Pharmaceuticals worth $8.78M as of Q2 2026.
Scotia Capital bought 1,548 Eupraxia Pharmaceuticals shares in Q2 2026, an estimated $10.7K.
Eupraxia Pharmaceuticals made up 0.03% of Scotia Capital's portfolio in Q2 2026, its #242 holding.
Scotia Capital first reported a position in Eupraxia Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
Scotia Capital's Eupraxia Pharmaceuticals position peaked at $9.6M in Q4 2025.
67 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.